Optimize IAS
  • Home
  • About Us
  • Courses
    • Prelims Test Series
      • LAQSHYA 2026 Prelims Mentorship
    • Mains Mentorship
      • Arjuna 2026 Mains Mentorship
  • Portal Login
  • Home
  • About Us
  • Courses
    • Prelims Test Series
      • LAQSHYA 2026 Prelims Mentorship
    • Mains Mentorship
      • Arjuna 2026 Mains Mentorship
  • Portal Login

EU regulator backs Eisai-Biogen Alzheimer’s drug

  • November 15, 2024
  • Posted by: OptimizeIAS Team
  • Category: DPN Topics
No Comments

 

 

EU regulator backs Eisai-Biogen Alzheimer’s drug

Sub: Sci

Sec: Health

Context:

  • The European Union’s drugs regulator, the European Medicines Agency (EMA), recently recommended the approval of Leqembi (a drug developed by Eisai and Biogen) for patients with early-stage Alzheimer’s disease.
  • This decision marks a reversal from its initial rejection four months ago and could potentially make Leqembi the EU’s first approved treatment for the condition if the recommendation is accepted by the European Commission.

Narrow Patient Group:

  • The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended Leqembi for a more specific group of patients: those with one or no copies of the ApoE4 gene variant.
  • These patients are less likely to experience severe side effects, such as brain swelling or bleeding, observed in persons with two copies of ApoE4 gene variant.

About Alzheimer’s disease:

  • Alzheimer’s disease is a progressive neurologic disorder that causes the brain to shrink (atrophy) and brain cells to die.
  • Alzheimer’s causes a gradual decline in memory, thinking, behaviour, and social skills, and it is the most common cause of dementia.
  • Its symptoms included memory loss, language problems, and unpredictable behaviour.
EU regulator backs Eisai-Biogen Alzheimer’s drug Science and tech

Recent Posts

  • Daily Prelims Notes 23 March 2025 March 23, 2025
  • Challenges in Uploading Voting Data March 23, 2025
  • Fertilizers Committee Warns Against Under-Funding of Nutrient Subsidy Schemes March 23, 2025
  • Tavasya: The Fourth Krivak-Class Stealth Frigate Launched March 23, 2025
  • Indo-French Naval Exercise Varuna 2024 March 23, 2025
  • No Mismatch Between Circulating Influenza Strains and Vaccine Strains March 23, 2025
  • South Cascade Glacier March 22, 2025
  • Made-in-India Web Browser March 22, 2025
  • Charting a route for IORA under India’s chairship March 22, 2025
  • Mar-a-Lago Accord and dollar devaluation March 22, 2025

About

If IAS is your destination, begin your journey with Optimize IAS.

Hi There, I am Santosh I have the unique distinction of clearing all 6 UPSC CSE Prelims with huge margins.

I mastered the art of clearing UPSC CSE Prelims and in the process devised an unbeatable strategy to ace Prelims which many students struggle to do.

Contact us

moc.saiezimitpo@tcatnoc

For More Details

Work with Us

Connect With Me

Course Portal
Search